Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
Follow KYNB
Alert me
Kyntra Bio Inc (KYNB) EV/Sales
As of 13 November 2026, Kyntra Bio Inc (KYNB) trades at a EV/Sales of 15.2×. Over the past ten years it has ranged from −1.4× (September 2023) to 35.8× (June 2018); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 8.6× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.5× | 392.51% |
| FY2024 | 3.0× | — |
| FY2023 | −0.3× | — |
| FY2022 | 8.4× | 94.12% |
| FY2021 | 4.3× | (71.69%) |
| FY2020 | 15.2× | 20.86% |
| FY2019 | 12.6× | (20.29%) |
| FY2018 | 15.8× | (32.39%) |
| FY2017 | 23.4× | 262.75% |
| FY2016 | 6.4× | (33.57%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 18.7× | 59.36% |
| Mar 2026 | 11.7× | (19.27%) |
| Dec 2025 | 14.5× | 53.35% |
| Sep 2025 | 9.5× | (52.02%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| JSPR Jasper Therapeutics, Inc. compare | n/m |
| ALLR Allarity Therapeutics, Inc. compare | n/m |
| NCEL NewcelX Ltd. compare | n/m |
| ADAPY Adaptimmune Therapeutics PLC compare | 0.1× |
| MRKR MARKER THERAPEUTICS, INC. compare | 1.8× |
| QNTM Quantum Biopharma Ltd. compare | 4.2× |
| KYNB Kyntra Bio Inc | 15.2× |
| MCRB Seres Therapeutics, Inc. compare | 46.7× |
| Biotechnology industry median | 8.6× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)